We joined other organizations around the world to demand Gilead to take immediate actions to ensure rapid availability, affordability and accessibility of its experimental therapy Remdesivir for the
treatment of COVID-19, if the clinical trials results demonstrate efficacy.
The FDA granted the request to Gilead on Monday March 30th, 2020. This meant Gilead would have 7 years of market exclusivity –if the drug was registered for COVID-19.
But civil society made huge pressure and Gilead withdrew the request on Wednesday April 1st 2020.
This is crucial as Gilead has filed patents in 70 Low and middle income countries and has sought further monopoly (beyond the 20 year patent term) in some countries such as in the US. We are disappointed the company has chosen to seek orphan drug designation from the US Food and Drug Administration. Click here to read more about this compaign